JAK2STAT5

JAK2STAT5 refers to the signaling axis in which the non-receptor tyrosine kinase JAK2 activates the transcription factor STAT5 in response to cytokine receptor engagement. JAK2 is part of the JAK family that associates with type I and II cytokine receptors. STAT5 comprises two highly related proteins, STAT5A and STAT5B, which upon activation dimerize and translocate to the nucleus to regulate gene expression.

Activation occurs when a cytokine binds its receptor, leading to receptor dimerization and cross-activation of bound JAK2. Activated JAK2 phosphorylates specific tyrosine residues on the receptor and on itself, creating docking sites for the SH2 domains of STAT5. STAT5 is phosphorylated on a critical tyrosine, dimerizes, and moves to the nucleus where it binds DNA at gamma-activated sequences to regulate genes involved in proliferation, survival, and differentiation, including BCL-XL, c-Myc, and Cyclin D1.

Physiological roles of JAK2-STAT5 signaling include regulation of erythropoiesis and thrombopoiesis via erythropoietin and thrombopoietin receptors, as well as involvement in development and function of certain immune cells and mammary gland biology through prolactin signaling.

Pathology can arise from constitutive or constitutively active JAK2-STAT5 signaling, such as via activating JAK2 mutations like V617F, which are linked to myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Aberrant STAT5 activation is also observed in various hematologic and solid tumors.

Therapeutically, JAK inhibitors (for example, ruxolitinib and fedratinib) target JAK2-STAT5 signaling to treat myeloproliferative neoplasms, though resistance and adverse effects pose challenges. Negative regulation is provided by SOCS proteins, PIAS, and protein tyrosine phosphatases that limit JAK2 or STAT5 activity.